Print
Email
Print Edition Stories
Incoming Covidien CEO José (Joe) E. Almeida will start his new job on July 1 with a new cadre of executives. Three months after announcing its succession plan for the CEO job, Covidien (NYSE: COV) on Wednesday announced a shake-up of top leadership intended to “streamline” the company’s organization.
James M. Muse, senior vice president, global supply chain, will retire after 32 years with the company. Scott Flora, president, surgical devices, will leave Covidien after five years in the role, “to pursue other career opportunities,” the company said in a press release.
Covidien is appointing Bryan C. Hanson to replace Flora as president of the surgical devices group. Hanson will also maintain responsibility for Covidien’s energy-based devices businesses. An employee since 1992, he’s currently president of that division.
Peter L. Wehrly will take on responsibility for the company’s vascular therapies businesses, in addition to the respiratory and monitoring solutions division, where he is already president.
Michael Sgrignari is named senior vice president, quality and operations.
Hanson, Wehrly and Sgrignari will report to Almeida, president, medical devices and CEO-elect. The position of president, medical devices, will be eliminated, the company said, but medical devices will remain an external reporting segment.
The changes are set to take effect July 1.
A health care products provider, Covidien has its global headquarters in Dublin, Ireland. Its U.S. headquarters are in Mansfield.
The company announced in March that CEO Richard Meelia, 62, will retire, effective July 1, to be replaced by Almeida, 48.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
